Trial Profile

Long Term Follow-up for Subjects Who Previously Participated in the NTXMCO-002 RESTORE Study

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 26 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sonpiretigene isteparvovec (Primary)
Indications Retinitis pigmentosa
Focus Adverse reactions
Acronyms REMAIN
Sponsors Nanoscope Therapeutics

Most Recent Events

24 Mar 2025 Status changed from recruiting to active, no longer recruiting.
04 Feb 2025 According to a Nanoscope Therapeutics media release, data from this study will be presented at the The Macula Society 48th Annual Meeting on 13 th feb 2025.
04 Feb 2025 According to a Nanoscope Therapeutics media release, data from this study will be presented at the Bascom Palmer Eye Institute's 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting on 8th Feb 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com